ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
Month: June 2011
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.
June 23-24 OneMedForum New York
OneMedPlace Trans-Atlantic Conference on June 23rd-24th is a gathering of fast growing, emerging healthcare and life science companies in Europe and North America. Its sixth […]
Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections
The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.
Small Bone Innovations Addresses Unmet Needs in Joint Replacement
Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.
OXiGENE Releases Promising Phase Two Data For Lung Cancer Drug
OXiGENE shares rose in pre-market trading Monday
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
June 22-23 2011 Wells Fargo Securities Healthcare Conference
Description: Explore the trends driving business in the Biotechnology, Health Care Facilities, Managed Care, Medical, Technology/Devices, Pharma Services, and Pharmaceuticals sectors. For additional details, please […]
Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant
Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program